Anti-hyperlipidemic

Aurantio-obtusin
Catalog No: CFN99732

Aurantio-obtusin possesses anti-allergic, vasorelaxation, hypotensive and hypolipidemic effects, it is a promising osteoanabolic compound with potential therapeutic applications in the prevention of osteoporosis and other metabolic bone diseases. Aurantio-obtusin can inhibit allergic responses in IgE-mediated mast cells and anaphylactic models, it suppresses degranulation, histamine production, and reactive oxygen species generation and inhibits the production and mRNA expression of tumor necrosis factor-α and interleukin-4, and also suppresses the prostaglandin E2 production and expression of cyclooxygenase 2.
Nuciferine
Catalog No: CFN99733

Nuciferine possesses anti-diabetic, anti-obesity, anti-hyperlipidemia, anti-hypotensive, anti-arrhythmic, vasorelaxant, and insulin secretagogue activities. Nuciferine may be potential for the prevention and treatment of hyperuricemia with kidney inflammation. It inhibited tumor-promoting effect of nicotine involving Wnt/β-catenin signaling in non-small cell lung cancer.
Rhodionin
Catalog No: CFN99758

Rhodionin and rhodionin can inhibit cytochrome P450 2D6 non-competitively with high specificity which could have implications for interactions with co-administered drugs; they can significantly suppress the elevation of the postprandial blood triglyceride level, suggests that they may be to the treatment of lifestyle-related diseases such as hyperlipidemia and exogeneous obesity and to health foods. Rhodionin has antioxidant activity, it exhibits potent 1,1-diphenyl-2-picryl-hydrazyl (DPPH) free radical scavenging activities, with IC50 values of 19.49 ± 0.21 uM.
Diosgenin glucoside
Catalog No: CFN99760

Diosgenin glucoside and other synthetic glycosides with similar activities may be of use in the management of hypercholesterolemia and atherosclerosis.
beta-Amyrin acetate
Catalog No: CFN99679

beta-Amyrin acetate has anti-inflammatory, antioxidant, and antidyslipidemic activities, it shows significant HMG-CoA-reductase and sEH inhibition. beta-Amyrin acetate also exhibits weak-moderate antiproliferative activity against the A2780 human ovarian cancer cell line.